Use of n6-benzylaminopurine as an appetite suppressant

Abstract

Disclosed herein is the use of N6-benzylaminopurine (BAP) as an appetite suppressant in animals including humans. The results of studies demonstrate the use of BAP as an appetite suppressant in animals, and the use of this common agricultural supplement for plant growth can be used to help to alleviate the ever-growing obesity pandemic afflicting modern society.

Therefore what is claimed is: 
     
         1 . An appetite suppressant administered to a subject, comprising:
 N6-benzylaminopurine and derivatives thereof formulated in an administrable form to the subject.   
     
     
         2 . The appetite suppressant according to  claim 1 , wherein the N6-benzylaminopurine is present in the administrable form in a concentration range from about 50 to about 2000 milligrams/kilogram of the subject's weight. 
     
     
         3 . The appetite suppressant according to  claim 1 , wherein the N6-benzylaminopurine is present in the administrable form in a concentration range from about 100 to about 500 milligrams/kilogram of the subject's weight. 
     
     
         4 . The appetite suppressant according to  claim 1 , wherein the N6-benzylaminopurine is present in the administrable form in a concentration range from about 150 to about 300 milligrams/kilogram of the subject's weight. 
     
     
         5 . The appetite suppressant according to  claim 1 , wherein the N6-benzylaminopurin is present in the administrable form in a concentration of about  200  milligrams/kilogram of the subject's weight. 
     
     
         6 . The appetite suppressant according to any one of  claims 1 to 5 , wherein the N6-benzylaminopurine is in an ingestible solid tablet form. 
     
     
         7 . The appetite suppressant according to any one of  claims 1 to 5 , wherein the N6-benzylaminopurine is in a powder form encased in an ingestible capsule. 
     
     
         8 . The appetite suppressant according to any one of  claims 1 to 5 , wherein the N6-benzylaminopurine is in the form of a liquid. 
     
     
         9 . The appetite suppressant according to  claim 8 , wherein the liquid is any in which that N6-benzylaminopurine is soluble. 
     
     
         10 . The appetite suppressant according to  claim 8 , wherein the liquid includes 70% ethanol, a solution of 0.02 M NaOH with 2% erythritol or water. 
     
     
         11 . The appetite suppressant according to  claim 8 , wherein the liquid is formulated as an administrable intranasal spray. 
     
     
         12 . The appetite suppressant according to any one of  claims 1 to 5 , wherein the N6-benzylaminopurine is in the form of an ingestible emulsion. 
     
     
         13 . The appetite suppressant according to  claim 12 , wherein the emulsion comprises a 50% honey format with about 0.5% carboxymethyl cellulose. 
     
     
         14 . The appetite suppressant according to any one of  claims 1 to 13 , wherein the N6-benzylaminopurine is used in combination with any other weight loss compounds. 
     
     
         15 . The appetite suppressant according to any one of  claims 1 to 14 , wherein the N6-benzylaminopurine is used in combination with any other diabetes medications, including insulin sensitizing compounds. 
     
     
         16 . The appetite suppressant according to any one of  claims 1 to 15 , wherein the N6-benzylaminopurine is used as a treatment for obesity-related diseases, including diabetes, heart disease, depression, fatty liver disease, diabetes-related comorbidities, and polycycstic ovarian disease. 
     
     
         17 . The appetite suppressant according to any one of  claims 1 to 16 , wherein the N6-benzylaminopurine is used in combination with any other therapeutic compounds known to increase appetite as a side effect. 
     
     
         18 . The appetite suppressant according to any one of  claims 1 to 17 , wherein the subject animal is any one of humans, human pets and farm animals. 
     
     
         19 . The use of N6-benzylaminopurine and derivatives thereof as an inhibitor of AMP-kinase. 
     
     
         20 . The use of N6-benzylaminopurine and derivatives as an inhibitor of mTORC120. 
     
     
         21 . The use of N6-benzylaminopurine according to  claim 19 , wherein the N 6 -benzylaminopurine is used as an inhibitor of mTORC1 acting through induction of Sestrin2 and Tuberous Sclerosis Complex 2 (TSC2). 
     
     
         22 . The use of N 6 -benzylaminopurine and derivatives as an inhibitor of neuropeptide Y. 
     
     
         23 . The appetite suppressant according to  claim 22 , wherein the N6-benzylaminopurine is used as an inhibitor of neuropeptide Y (NPY) acting through reduction of S6K phosphorylation and/or changes in transcription factors Early Growth Response Proteins 1 and 3 (Egr1 and Egr3). 
     
     
         24 . The use of N6-benzylaminopurine and derivatives as an inducer of proopiomelanocortin (POMC). 
     
     
         25 . The use of N6-benzylaminopurine and derivatives as an inducer of Akt phosphorylation and PI3 kinase. 
     
     
         26 . The use of N6-benzylaminopurine and derivatives as a repressor of ERK1/2 phosphorylation. 
     
     
         27 . The use of N6-benzylaminopurine and derivatives as a modulator of nucleoside diphosphate kinase (NDPK). 
     
     
         28 . The use of N6-benzylaminopurine and derivatives as an inducer of insulin receptor. 
     
     
         29 . The use of N6-benzylaminopurine and derivatives to enhance glucose tolerance and improve insulin sensitivity. 
     
     
         30 . The use of N6-benzylaminopurine and derivatives according to any one of  claims 19 to 29 , wherein the subject is any one of humans, human pets, farm animals 
     
     
         31 . The use of kinetin as an appetite suppressant.